Journal of Pediatric Neurology 2019; 17(03): 118-122
DOI: 10.1055/s-0038-1626699
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Diagnosing Coexisting Conditions of Angelman and Klinefelter Syndromes Using Chromosomal Microarray

Melissa Wong
1   University of Washington School of Medicine, Seattle, Washington, United States
,
Catherine R. Paschal
2   Department of Pathology, Seattle Children's Hospital, Seattle, Washington, United States
,
Xiuhua Bozarth
1   University of Washington School of Medicine, Seattle, Washington, United States
3   Department of Neurology, Seattle Children's Hospital, Seattle, Washington, United States
› Author Affiliations
Further Information

Publication History

13 November 2017

01 January 2018

Publication Date:
07 February 2018 (online)

Abstract

We report here a 4-year-old male patient who presented with clinical features of Angelman syndrome (AS, OMIM 105830) including dysmorphic features, hypotonia, lack of language development, ataxia, severe developmental delay, and seizures. Due to insurance denial for DNA methylation test, a chromosomal microarray (CMA) was performed, which showed an approximately 5.0 Mb deletion of Prader–Willi/AS critical region (15q11.2 to q13.1). Subsequent Prader–Willi/AS methylation analysis was consistent with the diagnosis of AS. Gain of an X chromosome (Klinefelter syndrome, KS) was also detected by CMA. KS is not usually diagnosed before puberty due to lack of specific clinical features in early childhood. It is unclear if there is any direct association between these two genetic disorders. There has only been one other published case, to our knowledge, of a patient with coexistence of AS due to 15q11.2-q13 deletion and KS. CMA is a fast and effective diagnostic test to determine multiple genetic disorders. Early genetic diagnostic testing using CMA as an alternative first-step diagnostic genetic testing for children with clinical suspicion of AS would be beneficial.

 
  • References

  • 1 Dagli AI, Mueller J, Williams CA. . Angelman syndrome. 1998 Sep 15 (Updated May 14, 2015). In: Pagon RA, Adam MP, Ardinger HH, et al., eds. Gene Reviews [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1144 . Accessed November 11, 2017
  • 2 Petersen MB, Brøndum-Nielsen K, Hansen LK, Wulff K. Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county. Am J Med Genet 1995; 60 (03) 261-262
  • 3 Kyllerman M. On the prevalence of Angelman syndrome. Am J Med Genet 1995; 59 (03) 405 , author reply 403–404
  • 4 Lalande M, Calciano MA. Molecular epigenetics of Angelman syndrome. Cell Mol Life Sci 2007; 64 (7–8): 947-960
  • 5 Laan LA, Vein AA. Angelman syndrome: is there a characteristic EEG?. Brain Dev 2005; 27 (02) 80-87
  • 6 Luk HM, Lo IF. Angelman syndrome in Hong Kong Chinese: a 20 years' experience. Eur J Med Genet 2016; 59 (6–7): 315-319
  • 7 Sánchez J, Peciña A, Alonso-Luengo O. , et al. Atypical Association of Angelman Syndrome and Klinefelter Syndrome in a boy with 47,XXY karyotype and deletion 15q11.2-q13. Case Rep Genet 2014; 2014: 517091
  • 8 Tartaglia N, Cordeiro L, Howell S, Wilson R, Janusz J. The spectrum of the behavioral phenotype in boys and adolescents 47,XXY (Klinefelter syndrome). Pediatr Endocrinol Rev 2010; 8 (01) (Suppl. 01) 151-159
  • 9 Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A. ; Klinefelter ItaliaN Group (KING). Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. J Endocrinol Invest 2017; 40 (02) 123-134
  • 10 Simpson JL, de la Cruz F, Swerdloff RS. , et al. Klinefelter syndrome: expanding the phenotype and identifying new research directions. Genet Med 2003; 5 (06) 460-468
  • 11 Visootsak J, Ayari N, Howell S, Lazarus J, Tartaglia N. Timing of diagnosis of 47,XXY and 48,XXYY: a survey of parent experiences. Am J Med Genet A 2013; 161A (02) 268-272
  • 12 Visootsak J, Graham Jr JM. Klinefelter syndrome and other sex chromosomal aneuploidies. Orphanet J Rare Dis 2006; 1: 42
  • 13 Ramsden SC, Clayton-Smith J, Birch R, Buiting K. Practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes. BMC Med Genet 2010; 11: 70
  • 14 Diagnostic Testing Approach in Angelman Syndrome. Angelman Syndrome Foundation. Avaialble at: https://www.angelman.org/what-is-as/medical-information/diagnostic-testing . Accessed October 26, 2017
  • 15 Aksglaede L, Link K, Giwercman A, Jørgensen N, Skakkebaek NE, Juul A. 47,XXY Klinefelter syndrome: clinical characteristics and age-specific recommendations for medical management. Am J Med Genet C Semin Med Genet 2013; 163C (01) 55-63
  • 16 Rigamonti C, Vizziello P, Monti F. , et al. Klinefelter syndrome in preschool children: the importance of an early multidisciplinary approach for patients and families. Minerva Pediatr 2016
  • 17 Velagaleti GV, Kumar A, Lockhart LH, Matalon R. Patent ductus arteriosus and microdeletion 22q11 in a patient with Klinefelter syndrome. Ann Genet 2000; 43 (02) 105-107
  • 18 Lee Y, Quek SC, Chong SS, Tan AS, Lum JM, Goh DL. Clinical report: a case of Williams syndrome and Klinefelter syndrome. Ann Acad Med Singapore 2006; 35 (12) 901-904
  • 19 Rodrigues MA, Morgade LF, Dias LFA. , et al. Down-Klinefelter syndrome (48,XXY,+21) in a neonate associated with congenital heart disease. Genet Mol Res 2017; 16 (03) DOI: 10.4238/gmr16039780.